» Articles » PMID: 14623812

Noninvasive Arrhythmia Risk Stratification in Idiopathic Dilated Cardiomyopathy: Results of the Marburg Cardiomyopathy Study

Overview
Journal Circulation
Date 2003 Nov 19
PMID 14623812
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Arrhythmia risk stratification with regard to prophylactic implantable cardioverter-defibrillator therapy is a completely unsolved issue in idiopathic dilated cardiomyopathy (IDC).

Methods And Results: Arrhythmia risk stratification was performed prospectively in 343 patients with IDC, including analysis of left ventricular (LV) ejection fraction and size by echocardiography, signal-averaged ECG, arrhythmias on Holter ECG, QTc dispersion, heart rate variability, baroreflex sensitivity, and microvolt T-wave alternans. During 52+/-21 months of follow-up, major arrhythmic events, defined as sustained ventricular tachycardia, ventricular fibrillation, or sudden death, occurred in 46 patients (13%). On multivariate analysis, LV ejection fraction was the only significant arrhythmia risk predictor in patients with sinus rhythm, with a relative risk of 2.3 per 10% decrease of ejection fraction (95% CI, 1.5 to 3.3; P=0.0001). Nonsustained ventricular tachycardia on Holter was associated with a trend toward higher arrhythmia risk (RR, 1.7; 95% CI, 0.9 to 3.3; P=0.11), whereas beta-blocker therapy was associated with a trend toward lower arrhythmia risk (RR, 0.6; 95% CI, 0.3 to 1.2; P=0.13). In patients with atrial fibrillation, multivariate Cox analysis also identified LV ejection fraction and absence of beta-blocker therapy as the only significant arrhythmia risk predictors.

Conclusions: Reduced LV ejection fraction and lack of beta-blocker use are important arrhythmia risk predictors in IDC, whereas signal-averaged ECG, baroreflex sensitivity, heart rate variability, and T-wave alternans do not seem to be helpful for arrhythmia risk stratification. These findings have important implications for the design of future studies evaluating prophylactic implantable cardioverter-defibrillator therapy in IDC.

Citing Articles

The Influence of Arrhythmia on the Outcomes of Pediatric Patients with Idiopathic Dilated Cardiomyopathy.

Dalili M, Dastafshan M, Mahdavi M, Shahzadi H, Mortaz Hejri G, Rashidighader F Pediatr Cardiol. 2024; .

PMID: 39432098 DOI: 10.1007/s00246-024-03684-6.


JCS/JHRS 2022 Guideline on Diagnosis and Risk Assessment of Arrhythmia.

Takase B, Ikeda T, Shimizu W, Abe H, Aiba T, Chinushi M J Arrhythm. 2024; 40(4):655-752.

PMID: 39139890 PMC: 11317726. DOI: 10.1002/joa3.13052.


Anesthetic Management of Patients with Dilated Cardiomyopathy Undergoing Noncardiac Surgery.

Li M, Huang H Medicina (Kaunas). 2023; 59(9).

PMID: 37763685 PMC: 10533037. DOI: 10.3390/medicina59091567.


T-Wave Analysis on the 24 h Holter ECG Monitoring as a Predictive Assessment of Major Adverse Cardiovascular Events in Patients with Myocardial Infarction: A Literature Review and Future Perspectives.

Duca S, Roca M, Costache A, Chetran A, Afrasanie I, Miftode R Life (Basel). 2023; 13(5).

PMID: 37240799 PMC: 10222557. DOI: 10.3390/life13051155.


Dilated Cardiomyopathy: A Comprehensive Approach to Diagnosis and Risk Stratification.

Ferreira A, Ferreira V, Antunes M, Lousinha A, Pereira-da-Silva T, Antunes D Biomedicines. 2023; 11(3).

PMID: 36979813 PMC: 10044994. DOI: 10.3390/biomedicines11030834.